(56) References

Cited: REICHERT JANICE M: "Antibody-based therapeutics to watch in 2011", MABS, vol.3, no.1, January 2011 (2011-01), pages 76-99, XP002688560,, Sanofi: "Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients (RA-MOBILITY)", ClinicalTrials.gov ( U.S. National Institutes of Health) , 2 February 2010 (2010 -02-02), XP002688561, Retrieved from the Internet: URL:http://www.clinicaltrials.gov/ct2/show /NCT01061736?term=sarilumab&rank=5 [retrieved on 2012-12-05], RADIN1 A ET AL: "Safety and effects on markers of inflammation of subcutaneously administered regn88/sar153191 (regn88), an interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis: findings from phase 1 studies", ANNALS OF THE RHEUMATIC DISEASES, vol.69, no. Suppl.3, 1 January 2010 (2010-01-01), page 99, XP008158577, BRITISH MEDICAL ASSOCIATION, LONDON, GB ISSN: 0003-4967, RADIN AR ET AL: "REGN88/SAR153191 a fully human inerleukin-6 receptor rnonioclonal anlibody, reduces acute phase reactants in patients with rheumatoid arthritis: preliminary observations", LY2439821, A HUMANIZED ANTI-INTERLEUKIN-17 MONOCLONAL ANTIBODY, IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS: A PHASE I RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY,, 1 January 2010 (2010-01-01), page S1121, XP008158581, ISSN: 1529-0131, Sanofi and Regeneron present results from pivotal phase 3 studys of sarilumab at american college of rheumatology annual meeting, BIOLOGICAL ABSTRACTS, vol.231 November 2014 (2014-11-01), Philadelphia, PA, US, abstract no.: 2823, Roy Fleischmann, Dennis L. Decktor, Chunpeng Fan, Hubert Van Hoogstraten and Mark C Genovese: "Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study", page S1232,, Tarrytown Paris ET AL: "Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis", , 12 July 2011 (2011 -07-12), XP055165299, Retrieved from the Internet: URL:http://investor.regeneron.com/common/d ownload/download.cfm?companyid=REGN&fileid =482054&filekey=687FE312-DCDE-4686-8C7D-828898B48C7D&filename=590869.pdf [retrieved on 2015-01-27], Sanofi and Regeneron announce positive topline results from phase 3 studies with sarilumab in patients with rheumatoid arthritis, Sanofi: "Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-alpha Blockers", ClinicalTrials.gov ( U.S. National Institutes of Health) , 7 October 2010 (2010-10-07), XP002688562, Retrieved from the Internet: URL:http://www.clinicaltrials.gov/ct2/show /NCT01217814?term=sarilumab&rank=1 [retrieved on 2012-12-05]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/